Rockwell Medical Announces Second Quarter 2026 Results
Business Wire (Thu, 13-Aug 6:00 AM ET)
Rockwell Medical Advances Quality and Regulatory Leadership
Business Wire (Wed, 22-Jul 6:00 AM ET)
Rockwell Medical Maintains Nasdaq Listing After Regaining Compliance—What This Means for Investors
Market Chameleon (Mon, 20-Jul 5:38 AM ET)
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
Business Wire (Mon, 20-Jul 6:00 AM ET)
Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
Business Wire (Thu, 16-Jul 6:00 AM ET)
Rockwell Medical Announces 1-for-10 Reverse Stock Split
Business Wire (Mon, 29-Jun 6:00 AM ET)
Market Chameleon (Tue, 20-Jan 4:54 AM ET)
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
Rockwell Medical trades on the NASDAQ stock market under the symbol RMTI.
As of August 28, 2026, RMTI stock price climbed to $8.17 with 36,422 million shares trading.
RMTI has a beta of 0.49, meaning it tends to be less sensitive to market movements. RMTI has a correlation of 0.01 to the broad based SPY ETF.
RMTI has a market cap of $32.93 million. This is considered a Sub-Micro Cap stock.
Last quarter Rockwell Medical reported $18 million in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-57,600 and exceeded earnings estimates by $1.80.
In the last 3 years, RMTI traded as high as $51.50 and as low as $4.89.
The top ETF exchange traded funds that RMTI belongs to (by Net Assets): VTI, VXF.
RMTI has underperformed the market in the last year with a return of -44.4%, while SPY returned +20.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RMTI shares. However, RMTI has outperformed the market in the last 3 month and 2 week periods, returning +6.9% and +4.4%, while SPY returned +2.8% and -1.1%, respectively. This indicates RMTI has been having a stronger performance recently.
RMTI support price is $7.32 and resistance is $8.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RMTI shares will trade within this expected range on the day.
